BFM
ZVRA icon

Boothbay Fund Management’s Zevra Therapeutics ZVRA Stock Holding History

Boothbay Fund Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,943
Closed -$142K – 2440
2025
Q3 		$142K Buy
+14,943
New +$150K ﹤0.01% 1695
2025
Q1 		– Sell
-85,818
Closed -$716K – 1841
2024
Q4 		$716K Buy
+85,818
New +$733K 0.02% 744
2023
Q2 		– Sell
-16,747
Closed -$92.1K – 2378
2023
Q1 		$92.1K Buy
+16,747
New +$88.6K ﹤0.01% 1959
2022
Q1 		– Sell
-12,516
Closed -$109K – 2580
2021
Q4 		$109K Sell
12,516
-399,900
-97% -$3.57M ﹤0.01% 1696
2021
Q3 		$3.85M Sell
412,416
-29,000
-7% -$292K 0.11% 230
2021
Q2 		$5.66M Buy
+441,416
New +$4.74M 0.18% 122

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Boothbay Fund Management's ZVRA Position: Q4 2025 in Review

Boothbay Fund Management sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 14,943 shares — an estimated $142K sold.

Boothbay Fund Management first reported a position in ZVRA in Q2 2021 and held it in 6 quarters. The position peaked at $5.66M in Q2 2021. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Boothbay Fund Management reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 14,943 Zevra Therapeutics shares in Q4 2025, an estimated $142K.
  • Boothbay Fund Management first reported a position in Zevra Therapeutics in Q2 2021 and held it in 6 quarters.
  • Boothbay Fund Management's Zevra Therapeutics position peaked at $5.66M in Q2 2021.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.